Emergent BioSolutions EV/EBIT EBS

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: 6.4×
10-year median: 12.8×
Against its 10-year history: 4th; percentile: 0 is its lowest day, 100 its highest
10-year range: 4.9× to 86.1×
Peer median: 5.1×

Emergent BioSolutions' EV/EBIT is 6.4× as of Oct 23, 2026.

That is below its ten-year median of 12.8×, lower than on 96% of days in the last ten years.

Over that time it ranged from 4.9× in Nov 2021 to 86.1× in Feb 2020.

The median for 10 large drugmakers of a similar size is 5.1×.

EV/EBIT over time

median 12.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	6.4×	5.7×	14.9×
2025	9.2×	7.2×	9.2×
2024	n/m a value too high to mean anything
2023	8.7×	8.5×	9.4×
2022	8.1×	6.2×	11.8×
2021	8.9×	4.9×	25.3×
2020	18.6×	17.2×	86.1×
2019	73.1×	20.3×	74.2×
2018	20.2×	14.3×	25.9×
2017	15.0×	9.5×	15.1×
2016	10.7×	6.2×	14.0×
2015	14.9×	12.9×	30.9×
2014	28.8×	13.6×	42.6×
2013	14.0×	5.8×	14.0×
2012	5.9×	5.1×	8.3×

Against its peers

Companies in Drug Manufacturers - General nearest Emergent BioSolutions' size, closest first, today.

Company	EV/EBIT
EBSEmergent BioSolutions	6.4×
NATRNatures Sunshine Products	5.2×
ARVNArvinas	n/m
PBYIPuma Biotechnology	15.6×
IRWDIronwood Pharmaceuticals	3.5×
ZVRAZevra Therapeutics	2.9×
CRMDCorMedix	2.3×
COLLCollegium Pharmaceutical	9.4×
ABUSArbutus Biopharma	4.9×
AMPHAmphastar Pharmaceuticals	12.2×
OMEROmeros	n/m
Peer median	5.1×

Where Emergent BioSolutions ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Emergent BioSolutions

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.